Lupin up on US regulatory approval for generic drug

Lupin up on US regulatory approval for generic drug

Shares in Lupin Ltd gain 1.6 per cent after US Food and Drug Administration gave a tentative approval for generic version of cholesterol drug niacin, a form of vitamin B, on Monday.

Analysts tracking the sector say niacin's US sales are  US$1.2 billion, out of which Lupin can make US$30 million in sales annually.

 

More about

Purchase this article for republication.

BRANDINSIDER

SPONSORED

Most Read

Your daily good stuff - AsiaOne stories delivered straight to your inbox
By signing up, you agree to our Privacy policy and Terms and Conditions.